METROPOLIS Metropolis Healthcare Q4 FY25 results (Jan–Mar 2025) and concall
Metropolis Healthcare delivered robust FY25 results with 12% revenue growth and 14% adjusted EBITDA growth, driven by strong B2C performance and strategic acquisitions. While Q4 reported EBITDA was affected by one-time costs, the company is poised for significant expansion in North India and aims for 100 bps margin expansion and 25-26% overall revenue growth in FY26 through organic growth and seamless integration of new assets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 11 | 4 |
| EBITDA | 72 | 62 |
| Net profit | 31 | 29 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
